– USA, NJ – UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of Dan Wildman to its Board of Directors, effective immediately.
“We are pleased to welcome Dan Wildman to UroGen’s Board of Directors. Dan is an accomplished global leader in the medical device and pharmaceutical industry with a long track record of bringing innovation and life-saving solutions to surgeons and patients,” said CEO, Liz Barrett.
About Dan Wildman
Dan Wildman is Chairman of the Board of Progenerative Medical, Inc., a 40-year medical device industry veteran, and Strategic Advisor to several medical device and pharmaceutical companies. He spent most of his career with Johnson & Johnson, where he most recently led the Digital Surgery Strategy Initiative, which developed an integrated robotic surgery strategy for the Company. Prior to Digital Surgery, Dan led DuPuy Synthes Spine, the second-largest surgery business in the world where he engineered and executed an integrated turn-around plan for the Company.
Before DuPuy Synthes, Dan Wildman served as Worldwide President of Ethicon Biosurgery, a division of Ethicon, Inc., where he focused on the development and commercialization of biomaterial, biologic and combination products that changed the standard of care for intraoperative hemostasis. In his role, Dan transitioned the company from Advanced Wound Care to Biosurgery through a combination of acquisitions, divestitures, and internal capability development. The Biosurgery business at Ethicon continues to be one of the fastest-growing companies in J&J’s portfolio.
“I am impressed with UroGen’s innovative technology and its potential to disrupt other areas of urologic oncology,” said Dan Wildman. “As a member of the board, I’m excited to work with this leadership team to explore more opportunities to transform patient care.”
Before J&J, Dan Wildman spent 10 years with Boston Scientific Corporation in various sales, marketing, operations, and strategic planning roles.
Dan Wildman received a Bachelor of Arts degree in Economics from St. Lawrence University in NY.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable more prolonged exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
For more information https://www.urogen.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
